{
    "clinical_study": {
        "@rank": "70634", 
        "acronym": "SOPRA", 
        "arm_group": [
            {
                "arm_group_label": "Selinexor (KPT-330)", 
                "arm_group_type": "Experimental", 
                "description": "~55 mg/m2 twice weekly (Monday and Wednesday or Tuesday and Thursday). Dosed based on the patient's body surface area (BSA)"
            }, 
            {
                "arm_group_label": "Physician's Choice", 
                "arm_group_type": "Active Comparator", 
                "description": "One of the following 3 conventional care regimens will be selected by the physician:\nbest supportive care (BSC) including blood product transfusions, antimicrobials, growth factors as needed, and hydroxyurea;\nBSC + low dose Ara-C, 20 mg bid by subcutaneous (sc) injection daily on days 1-10/14 days (20/28 doses) to be repeated at 28 to 42 day intervals;\nBSC + hypomethylating agent: azacitidine 75 mg/m2 by sc injection daily on days 1-7 (7 doses) to be repeated at 28 day intervals, or decitabine (20 mg/m2 IV over 1 hour daily on Days 1-5 to be repeated at 28 day intervals)."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized, multicenter, open-label, Phase 2 study of the SINE Selinexor given\n      orally versus specified investigator choices (one of three potential salvage therapies).\n      Patients age \u2265 60 years with relapsed/refractory AML of any type except for AML M3, after\n      one prior therapy only, who have never undergone and who are not currently eligible for stem\n      cell transplantation and are currently deemed unfit for intensive chemotherapy."
        }, 
        "brief_title": "Selinexor (KPT-330) in Older Patients With Relapsed AML", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Myeloid Leukemia (AML)", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a randomized, multicenter, open-label phase 2 study of the SINE Selinexor given\n      orally versus restricted investigator choice (i.e., one of three potential salvage\n      therapies).\n\n      Patients who have never been transplant eligible, are currently deemed unfit for intensive\n      chemotherapy, \u2265 60 years old, who have AML (except Acute Promyelocytic Leukemia:  APL, AML\n      M3) after one prior treatment of either hypomethylating agent or a regimen including Ara-C,\n      and are meeting the inclusion and exclusion criteria will be randomized to receive either\n      oral Selinexor or physician's choice (one of three potential treatments: best supportive\n      care (BSC) alone, or BSC + hypomethylating agent, or BSC + low dose Ara-C until disease\n      progression, death or intolerance has occurred."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u2265 60 years with relapsed/refractory AML of any type except for AML M3, after 1\n             prior therapy only, who have never undergone, and who are not currently eligible for,\n             stem cell transplantation, and are currently deemed unfit for intensive chemotherapy.\n\n          -  ECOG \u2264 2.\n\n          -  Must have available archival or recently acquired bone marrow biopsy/aspiration or\n             tumor tissue for central review to be eligible.\n\n          -  Relapsed or refractory AML, defined as either: recurrence of disease after a complete\n             remission (CR), or failure to achieve CR with initial therapy.\n\n          -  Must have received only 1 prior line of therapy given at standard doses.  Prior\n             therapy must have included: (1) A regimen including cytosine arabinoside (Ara-C)\n             chemotherapy (low dose AraC alone does qualify for prior chemotherapy) or (2) a\n             hypomethylating agent.\n\n          -  At least 2 weeks must have elapsed since the last anti-leukemia treatment (with the\n             exception of hydroxyurea) before first dose in this study.\n\n        Exclusion Criteria:\n\n          -  Treatment with any investigational agent within 3 weeks prior to first dose in this\n             study.\n\n          -  Presence of central nervous system (CNS) leukemia.\n\n          -  In blast transformation of chronic myeloid leukemia (CML).  Prior myelodysplastic\n             syndrome (MDS) is acceptable; prior treatment for MDS does not count as an AML\n             therapy.\n\n          -  Major surgery within 2 weeks of first dose of study drug.  Patients must have\n             recovered from the effects of any surgery performed greater than 2 weeks previously.\n\n          -  Concurrent active malignancy under treatment.\n\n          -  Known active hepatitis B virus (HBV) or C virus (HCV) infection; or known to be\n             positive for HCV ribonucleic acid (RNA) or HBsAg (HBV surface antigen).\n\n          -  Known HIV infection.\n\n          -  Unable to swallow tablets, or patients with malabsorption syndrome, or any other\n             disease significantly affecting gastrointestinal function."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "60 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02088541", 
            "org_study_id": "KCP-330-008"
        }, 
        "intervention": [
            {
                "arm_group_label": "Selinexor (KPT-330)", 
                "intervention_name": "Selinexor", 
                "intervention_type": "Drug", 
                "other_name": "KPT-330"
            }, 
            {
                "arm_group_label": "Physician's Choice", 
                "intervention_name": "Hydroxyurea", 
                "intervention_type": "Drug", 
                "other_name": "Hydroxycarbamide"
            }, 
            {
                "arm_group_label": "Physician's Choice", 
                "intervention_name": "Ara-C", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Cytarabine", 
                    "cytosine arabinoside", 
                    "Cytosar-U", 
                    "Depocyt"
                ]
            }, 
            {
                "arm_group_label": "Physician's Choice", 
                "intervention_name": "azacitidine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "5-azacytidine", 
                    "Vidaza"
                ]
            }, 
            {
                "arm_group_label": "Physician's Choice", 
                "intervention_name": "Decitabine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Dacogen", 
                    "5-aza-2'-deoxycytidine,"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Azacitidine", 
                "Cytarabine", 
                "Decitabine", 
                "Hydroxyurea"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Relapsed/Refractory Acute Myeloid Leukemia", 
            "Acute Myeloid Leukemia", 
            "AML", 
            "Karyopharm", 
            "Selinexor", 
            "KPT-330"
        ], 
        "lastchanged_date": "April 14, 2014", 
        "location": [
            {
                "contact": {
                    "email": "hliu2@medicine.bsd.uchicago.edu", 
                    "last_name": "Hongtao Liu, M.D., Ph.D.", 
                    "phone": "773-702-6180"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60637"
                    }, 
                    "name": "University of Chicago Medicine"
                }, 
                "investigator": {
                    "last_name": "Hongtao Liu, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ngabrailmd@aol.com", 
                    "last_name": "Nashat Gabrail, M.D.", 
                    "phone": "330-492-3345"
                }, 
                "facility": {
                    "address": {
                        "city": "Canton", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44718"
                    }, 
                    "name": "Gabrail Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Nashat Gabrail, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients \u2265 60 Years Old With Relapsed/Refractory AML Who Are Ineligible for Intensive Chemotherapy and/or Transplantation", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada", 
                "Denmark: Danish Health and Medicines Authority"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine overall survival (OS) of Selinexor as compared to physician choice (PC).", 
            "measure": "Overall survival", 
            "safety_issue": "No", 
            "time_frame": "From the date of randomization until the date of death, or study end (up to approximately 104 weeks)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02088541"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Survival at 3 months post-randomization", 
            "measure": "3 month survival", 
            "safety_issue": "No", 
            "time_frame": "up to 3 months"
        }, 
        "source": "Karyopharm Therapeutics, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Karyopharm Therapeutics, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}